Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes

Vaccine

Volumn 17, Issue 3, 1999, Pages 261-268

  Nam, Jae Hwan ^a,b   Wyatt, Linda S ^c   Chae, Soo Lim ^a   Cho, Hae Wol ^a   Park, Young Keun ^b   Moss, Bernard ^c  

^a Korea National Institute of Health   (South Korea)

^b Korea University   (South Korea)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Japanese encephalitis virus; MVA strain; Vaccinia virus

Indexed keywords

ENCEPHALITIS VACCINE; MEMBRANE PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL MODEL; ANTIBODY TITER; ARTICLE; ATTENUATION; EPIDEMIC ENCEPHALITIS; FLOW CYTOMETRY; GENE EXPRESSION; GENE INSERTION; IMMUNIZATION; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMOTER REGION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ENCEPHALITIS, JAPANESE; GENE EXPRESSION REGULATION, VIRAL; IMMUNIZATION; MICE; MICE, INBRED ICR; RECOMBINATION, GENETIC; SPECIES SPECIFICITY; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 0344588807     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00156-X     Document Type: Article

References (30)

1. Igarashi A. Epidemiology and control of Japanese encephalitis. Wld. Hlth. Statist. Quart. 45:1992;299-305.
2. McAda P., Mason P.W., Schmaljohn C.S., Dalrymple J.M., Mason T.L., Fournier M.J. Partial nucleotide sequence of the Japanese encephalitis virus genome. Virology. 158:1987;348-360.
3. Sumiyoshi H., Mori C., Fuke I.et al. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology. 161:1987;497-510.
4. Konishi E., Mason P.W. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J. Virol. 67:1993;1672-1675.
5. Flamand M., Deubel V., Girard M. Expression and secretion of Japanese encephalitis virus nonstructural protein NS1 by insect cells using a recombinant baculovirus. Virology. 191:1992;826-836.
6. Matsuura Y., Miyamoto M., Sato T., Morita C., Yasui K. Characterization of Japanese encephalitis virus envelope protein expressed by recombinant baculoviruses. Virology. 173:1989;674-682.
7. Yasuda A., Kimura-Kuroda J., Ogimoto M.et al. Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express preM and E glycoproteins of Japanese encephalitis virus. J. Virol. 64:1990;2788-2795.
8. Mason P.W., Pincus S., Fournier M.J., Mason T.L., Shope R.E., Paoletti E. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology. 180:1991;294-305.
9. Konishi E., Pincus S., Fonseca B.A.L., Shope R.E., Paoletti E., Mason P.W. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology. 185:1991;401-410.
10. Konishi E., Pincus S., Paoletti E., Laegreid W.W., Shope R.E., Mason P.W. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology. 190:1992;454-458.
11. Konishi E., Pincus S., Paoletti E., Shope R.E., Mason P.W. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine. 12:1994;633-638.
12. Pugachev K.V., Mason P.W., Frey T.K. Sindbis vectors suppress secretion of subviral particles of Japanese encephalitis virus from mammalian cells infected with SIN-JEV recombinants. Virology. 209:1995;155-168.
13. Pugachev K.V., Mason P.W., Shope R.E., Frey T.K. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology. 212:1995;587-594.
14. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1991;1031-1038.
15. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 238:1997;198-211.
16. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schäfer H., Holzner A. MVA-stufenimpfung gegen pocken. Klinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA. Dtsch. Med. Wschr. 99:1974;2386-2392.
17. Mayr A., Stickl H., Müller H.K., Danner K., Singer H. Der pockenimpfstamm MVA: Marker, genetische struktur, erfahrungen mit der parenteralen schutzimpfung und verhalten im abwehrgeschwächten organismus. Zbl. Bakt. Hyg. 167:1978;375-390.
18. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA. 89:1992;10847-10851.
19. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 12:1994;1032-1040.
20. Bender B., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., Small P.A.J. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70:1996;6418-6424.
21. Wyatt L.S., Shors S.T., Murphy B.R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine. 14:1996;1451-1458.
22. Hirsch V.M., Fuerst T.R., Sutter G.et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:1996;3741-3752.
23. Chung Y.J., Nam J.H., Ban S.J., Cho H.W. Antigenic and genetic analysis of Japanese encephalitis viruses isolated from Korea. Am. J. Trop. Med. Hyg. 55:1996;91-97.
24. Nam J.H., Chung Y.J., Ban S.J., Kim E.J., Park Y.K., Cho H.W. Envelope gene sequence variation among Japanese encephalitis viruses isolated in Korea. Acta Virol. 40:1996;303-309.
25. Chakrabarti S., Sisler J.R., Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques. 23:1997;1094-1097.
26. Cho H.W., Kim C.L., Ban S.J., Nam J.H., Chung Y.J., Lee Y.J. Antigenic analysis of JE virus isolated from mosquitos (C.t.) in Korea and the development of a rapid diagnosis for JE by using monoclonal antibody. Rep. Natl. Inst. Health. 31:1994;130-138.
27. Clarke D.H., Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am. J. Trop. Med. Hyg. 7:1958;561-573.
28. Tesh R.B., Duboise S.M. Viremia and immune response with sequential phlebovirus infections. Am. J. Trop. Med. Hyg. 36:1987;662-668.
29. Kanesathasan N., Smucny J.J., Konishi E.et al. Evaluation of immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in humans. Am. J. Trop. Med. Hyg. 53:1995;139.
30. Durbin, A.P., Wyatt, L.S., Siew, J., Moss, B., Murphy. B.R. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine 1998;16:1324-30.